Our People

TAN Soo Yong

Contact Information

Email

pattsy@nus.edu.sg

Telephone

+65 6772 4300

Research Themes

  • HAEMATOLYMPHOID CANCER
  • MICRORNA BIOLOGY & DIAGNOSTICS
  • AI PATHOLOGY

Other Information

ORCID

orcid.org/0000-0002-6348-2823

Tan Soo Yong

MBBS, DipRCPath, FRCPath, DMJ(Path), DPhil(Oxon)
ASSOCIATE PROFESSOR, NUS
SENIOR CONSULTANT, NUH
LAB DIRECTOR, IMCB

RESEARCH FOCUS

  • Investigating the molecular mechanism driving lymphomagenesis and researching novel therapeutics for patients with lymphomas
  • Developing microRNA-based diagnostic and prognostic assay for lymphomas
  • Developing of image analysis tools, deep learning and medical image processing for digital pathology

BIOGRAPHY

A/Prof Tan Soo Yong obtained his medical qualifications from the National University of Singapore and underwent postgraduate training in Singapore and in the University of Sheffield, United Kingdom. Qualifying in both forensic and histopathology, he is a Fellow of the Royal College of Pathologists (UK) and a Diplomate of the Society of Apothecaries of London. A/Prof Tan obtained his PhD from Oxford University, working in the field of haematopathology.

His current research interest is in the pathology of intestinal T-cell lymphomas, miRNA profiling of lymphoid neoplasms and development of AI-enhanced diagnostic pathology algorithms. He is a member of the International Lymphoma Study Group (ILSG) and an author of the WHO Classification of Tumours of Haematolymphoid, Skin and Digestive systems. A/Prof Tan sits on the Editorial Board of the Journal of Haematopathology and on the Advisory Boards of biotech companies. A/Prof Tan is also Director of the Advanced Molecular Pathology Laboratory (AMPL) in the Institute of Cell and Molecular Biology and Adjunct Clinical Scientist in the Nanobiology Laboratory, A*STAR.

Professional / Clinical experience

• Head and Senior Consultant, Department of Pathology, National University Hospital, 2016-

• Senior Consultant, Department of Pathology, Singapore General Hospital, 2006-2016

• Consultant, Department of Pathology, Singapore General Hospital July 2004-2006

• Consultant, Department of Pathology & Laboratory Medicine, Tan Tock Seng Hospital Singapore 2002-2004

• Associate Consultant, Department of Pathology & Laboratory Medicine, Tan Tock Seng Hospital Singapore 2001-2002

• Associate Consultant, Department of Forensic Medicine, Institute of Science and Forensic Medicine Apr 1999-2001

• Medical Officer Department of Forensic Medicine, Institute of Science and Forensic Medicine Apr 1996-1999

• Medical Officer, Department of Forensic Medicine, Institute of Science and Forensic Medicine,1992-1996

• Medical Officer, Ministry of Defence, 1990-1992

• House Officer, Ministry of Health, 1989-1990

Group Members

Tan Soo Yong-right

Recent Publications

Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma. Hoppe MM, et al. Cancer Discov. 2023 May 4;13(5):1144-1163.

Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. Ran XB, et. al. Cancer Res. 2023 Mar 15;83(6):922-938.

Tissue-Specific microRNA Expression Profiling to Derive Novel Biomarkers for the Diagnosis and Subtyping of Small B-Cell Lymphomas. Hue SS, Jin Y, Cheng H, Bin Masroni MS, Tang LWT, Ho YH, Ong DB, Leong SM, Tan SY.
Cancers (Basel). 2023 Jan 10;15(2):453.

Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.  Wai CMM, et al. Haematologica. 2022 Aug 1;107(8):1864-1879.

Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.
Hue SS, Ng SB, Wang S, Tan SY.
Cancers (Basel). 2022 May 18;14(10):2483. doi: 10.3390/cancers14102483.

RF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.
Amanda S, Tan TK, Ong JZL, Theardy MS, Wong RWJ, Huang XZ, Ali MZ, Li Y, Gong Z, Inagaki H, Foo EY, Pang B, Tan SY, Iida S, Sanda T.
Nat Commun. 2022 May 3;13(1):2420. doi: 10.1038/s41467-022-30053-9.

Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Ting CY, Tan SY, Gan GG, Zain SM, Pung YF, Ong DB, Bee PC.
Int J Lab Hematol. 2022 Oct;44(5):907-917. doi: 10.1111/ijlh.13928. Epub 2022 Jul 13.

Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract. Hue SS, et al. . Semin Diagn Pathol. 2021. 38(4):21-30.

Targeting N-myristoylation for therapy of B-cell lymphomas. Beauchamp E, et al. Nat Commun. 2020. 22;11(1):5348.

 

Scroll to Top